Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG527

—

e3a35207-f6d4-5fc4-9cef-2f881e5faa0f

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ANGIOGENESIS+0.382
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.342
  • HYPOXIA+0.289
  • GLYCOLYSIS+0.264
  • MYOGENESIS+0.238
  • CHOLESTEROL_HOMEOSTASIS+0.225
  • WNT_BETA_CATENIN_SIGNALING+0.221
  • UV_RESPONSE_DN+0.183
  • P53_PATHWAY+0.146
  • NOTCH_SIGNALING+0.122

Top 10 suppressed

  • MYC_TARGETS_V2-0.446
  • ALLOGRAFT_REJECTION-0.395
  • MYC_TARGETS_V1-0.389
  • INTERFERON_ALPHA_RESPONSE-0.325
  • E2F_TARGETS-0.318
  • OXIDATIVE_PHOSPHORYLATION-0.300
  • INTERFERON_GAMMA_RESPONSE-0.293
  • G2M_CHECKPOINT-0.273
  • UV_RESPONSE_UP-0.243
  • COMPLEMENT-0.192

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-FD-A3SM-01A-11R-A22U-07
bladder-landscape@3
——0.789
2SRR2932826
head-neck@1
——0.778
3X9d79253b.8c45.4bde.a42d.c399fb107400
lung-landscapes@6
—cohortMD20.773
4SRR8613703
breast-umap@18
—D0.770
5SRR8613758
breast-umap@18
—C0.767
6SRR2661579
melanoma-umap@29
——0.761
7SRR8613707
breast-umap@18
—C0.749
8SRR8613779
breast-umap@18
—D0.747
920030071.Her2HRpos
breast-umap@18
—A0.743
10TCGA-55-8505-01A-11R-2403-07
lung-landscapes@6
—cohortA40.742

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 25 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ANGIOGENESIS0.382Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.342Inavolisib— uncovered
HYPOXIA0.289Idelalisib— uncovered
GLYCOLYSIS0.264Inavolisib— uncovered
MYOGENESIS0.238Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.225Remibrutinib— uncovered
WNT_BETA_CATENIN_SIGNALING0.221Inavolisib— uncovered
UV_RESPONSE_DN0.183Inavolisib— uncovered
P53_PATHWAY0.146Idelalisib— uncovered
NOTCH_SIGNALING0.122Inavolisib— uncovered
APICAL_JUNCTION0.117Inavolisib— uncovered
MTORC1_SIGNALING0.115Inavolisib— uncovered
PANCREAS_BETA_CELLS0.115Cobimetinib— uncovered
ADIPOGENESIS0.113Inavolisib— uncovered
MITOTIC_SPINDLE0.094Inavolisib— uncovered
APOPTOSIS0.068Idelalisib— uncovered
COAGULATION0.063Binimetinib— uncovered
PI3K_AKT_MTOR_SIGNALING0.045Inavolisib— uncovered
TGF_BETA_SIGNALING0.044Inavolisib— uncovered
PROTEIN_SECRETION0.038Remibrutinib— uncovered